The Fas counterattack: A molecular mechanism of tumor immune privilege

Molecular Medicine

Volumn 3, Issue 5, 1997, Pages 294-300

  O'Connell, Joe ^a   Bennett, Michael W ^a   O'Sullivan, Gerald C ^a   Collins, J Kevin ^a   Shanahan, Fergus ^a,b  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b University College Cork and INFANT Centre   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN;

APOPTOSIS; CANCER IMMUNOLOGY; HUMAN; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION;

EID: 0030850696     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03401808     Document Type: Review

References (75)

1. Nagata S, Golstein P. (1995) The Fas death factor. Science 267: 1449-1456.
2. Yonehara S, Nishimura Y, Kishil S, et al. (1994) Involvement of apoptosis antigen Fas in clonal deletion of human thymocytes. Int. Immunol. 6: 1849-1856.
3. Alderson MR, Tough TW, Davis-Smith T, et al. (1995) Fas ligand mediates activation-induced cell death in human T lymphocytes. J. Exp. Med. 181: 71-77.
4. Daniel PT, Krammer PH. (1994) Activation induces sensitivity toward APO-1 (CD95)-mediated apoptosis in human B cells. J. Immunol. 152: 5624-5632.
5. Ju ST, Cui H, Panka DJ, Ettinger R, MarshakRothstein A. (1994) Participation of target Fas protein in apoptosis pathway induced by CD4+ Th1 and CD8+ cytotoxic T cells. Proc. Natl. Acad. Sci. U.S.A. 91: 4185-4189.
6. Berke G. (1995) The CTL's kiss of death. Cell 81: 9-12.
7. Stalder T, Hahn S, Erb P. (1994) Fas antigen is the major target molecule for CD4+ T cell-mediated cytotoxicity. J. Immunol. 152: 1127-1133.
8. Montel AH, Bochan MR, Hobbs JA, Lynch DA, Brahmi Z. (1995) Fas involvement in cytotoxicity mediated by human NK cells. Cell. Immunol. 166: 236-246.
9. Trauth BC, Klas C, Peters AMJ, et al. (1989) Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 245: 301-305.
10. Coney LR, Daniel PT, Sanborn D, et al. (1994) Apoptotic cell death induced by a mouse-human anti-APO-1 chimeric antibody leads to tumor regression. Int. J. Cancer 58: 562-567.
11. Lucking-Famira KM, Daniel PT, Möller P, Krammer PH, Debatin KM. (1994) APO-1 (CD95) mediated apoptosis in human T-ALL engrafted in SCID mice. Leukemia 8: 1825-1833.
12. Suda T, Okazaki T, Naito Y, et al. (1995) Expression of the Fas ligand in cells of T cell lineage. J. Immunol. 154: 3806-3813.
13. Hahne M, Renno T, Schroeter M, et al. (1996) Activated B cells express functional Fas ligand. Eur. J. Immunol. 26: 721-724.
14. Liles WC, Kiener PA, Ledbetter JA, Aruffo A, Klebanoff SJ. (1996) Differential expression of Fas (CD95) and Fas ligand on normal human phagocytes: Implications for the regulation of apoptosis in neutrophils. J. Exp. Med. 184: 429-440.
15. Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA. (1995) Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 270: 1189-1192.
16. Bellgrau D, Gold D, Selawry H, Moore J, Franzusoff A, Duke RC. (1995) A role for CD95 ligand in preventing graft rejection. Nature 377: 630-632.
17. O'Connell J, O'Sullivan GC, Collins JK, Shanahan F. (1996) The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J. Exp. Med. 184: 1075-1082.
18. Hahne M, Rimoldi D, Schroter M, et al. (1996) Melanoma cell expression of Fas(Apo-1/CD95) ligand: Implications for tumor immune escape. Science 274: 1363-1366.
19. Strand S, Hofmann WJ, Hug H, et al. (1996) Lymphocyte apoptosis induced by CD95 (Apo-1/Fas) ligand-expressing tumor cells - a mechanism of immune evasion? Nat. Med. 2: 1361-1366.
20. Robertson MJ, Manley TJ, Pichert G, et al. (1995) Functional consequences of APO-1/ Fas (CD95) antigen expression by normal and neoplastic hematopoietic cells. Leuk. Lymphoma. 17: 51-61.
21. Kotani T, Aratake Y, Kondo S, Tamura K, Ohtaki S. (1994) Expression of functional Fas antigen on adult T-cell leukemia. Leuk. Res. 18: 305-310.
22. Massaia M, Borrione P, Attisano C, et al. (1995) Dysregulated Fas and Bcl-2 expression leading to enhanced apoptosis in T cells of multiple myeloma patients. Blood 85: 3679-3687.
23. Westendorf JJ, Lammen JM, Jelinek DF, (1995) Expression and function of Fas (APO-1/CD95) in patient myeloma cells and myeloma cell lines. Blood 85: 3566-3576.
24. Shima Y, Nishimoto N, Ogata A, Fujii Y, Yoshizaki K, Kishimoto T. (1995) Myeloma cells express Fas antigen/APO-1 (CD95) but only some are sensitive to anti-Fas antibody resulting in apoptosis. Blood 85: 757-764.
25. Hata H, Matsuzaki H, Takeya M, et al. (1995) Expression of Fas/Apo-1 (CD95) and apoptosis in tumor cells from patients with plasma cell disorders. Blood 86: 1939-1945.
26. Mori S, Murakami-Mori K, Jewett A, Nakamura S, Bonavida B. (1996) Resistance of AIDS-associated Kaposi's sarcoma cells to Fas-mediated apoptosis. Cancer Res. 56: 1874-1879.
27. Owen-Schaub LB, Radinsky R, Kruzel E, Berry K, Yonehara S. (1994) Anti-Fas on nonhematopoietic tumors: Levels of Fas/ APO-1 and bcl-2 are not predictive of biological responsiveness. Cancer Res. 54: 1580-1586.
28. Weller M, Frei K, Groscurth P, Krammer PH, Yonekawa Y, Fontana A. (1994) Anti-Fas/ APO-1 antibody-mediated apoptosis of cultured human glioma cells. Induction and modulation of sensitivity by cytokines. J. Clin. Invest. 94: 954-964.
29. Keane MM, Ettenberg SA, Lowrey GA, Russell EK, Lipkowitz S. (1996) Fas expression and function in normal and malignant breast cell lines. Cancer Res. 56: 4791-4798.
30. Möller P, Koretz K, Leithauser F, et al. (1994) Expression of APO-1 (CD95), a member of the NGF/TNF receptor superfamily, in normal and neoplastic colon epithelium. Int. J. Cancer 57: 371-377.
31. Knipping E, Debatin K-M, Stricker K, Heilig B, Edar A, Krammer PH. (1995) Identification of soluble APO-1 in supernatants of human B- and T-cell lines and increased serum levels in B- and T-cell leukemias. Blood 85: 1562-1569.
32. Owen-Schaub LB, Angelo LS, Radinsky R, Ware CF, Gesner TG, Bartos DP. (1995) Soluble Fas/APO-1 in tumor cells: A potential regulator of apoptosis? Cancer Lett. 94: 1-8.
33. Tachibana O, Nakazawa H, Lampe J, Watanabe K, Kleihues P, Ohgaki H. (1995) Expression of Fas/APO-1 during the progression of astrocytomas. Cancer Res. 55: 5528-5530.
34. Natoli G, Ianni A, Costanzo A, et al. (1995) Resistance to Fas-mediated apoptosis in human hepatoma cells. Oncogens 11: 1157-1164.
35. Cascino I, Papoff G, De Maria R, Testi R, Ruberti G. (1996) Fas/Apo-1 (CD95) receptor lacking the intracytoplasmic signaling domain protects tumor cells from Fas-mediated apoptosis. J. Immunol. 156: 13-17.
36. Chinnaiyan AM, O'Rourke K, Tewari M, Dixit VM. (1995) FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 81: 505-512.
37. Stanger BZ, Leder P, Lee TH, Kim E, Seed B. (1995) RIP: A novel protein containing a death domain that interacts with Fas/APO-1 (CD95) in yeast and causes cell death. Cell 81: 513-523.
38. Chu K, Niu X, Williams LT. (1995) A Fas-associated protein factor, FAF1, potentiates Fas-mediated apoptosis. Proc. Natl. Acad. Sci. U.S.A. 92: 11894-11898.
39. Muzio M, Chinnaiyan AM, Kischkel FC, et al. (1996) FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell 85: 817-827.
40. Sato T, Irie S, Kitada S, Reed JC. (1995) FAP-1: A protein tyrosine phosphatase that associates with Fas. Science 268: 411-415.
41. Okura T, Gong L, Kamitani T, et al. (1996) Protection against Fas/Apo-1 and tumor necrosis factor-mediated cell death by a novel protein, sentrin. J. Immunol. 157: 4277-4281.
42. Enari M, Talanian RV, Wong WW, Nagata S. (1996) Sequential activation of ICE-like and CPP32-like proteases during Fas-mediated apoptosis. Nature 380: 723-726.
43. Los M, van de Craen M, Penning LC, et al. (1995) Requirement of an ICE/CED-3 protease for Fas/APO-1-mediated apoptosis. Nature 375: 81-83.
44. Srinivasula SM, Ahmad M, Fernandes-Alnemri T, Litwack G, Alnemri ES. (1996) Molecular ordering of the Fas-apoptotic pathway: The Fas/APO-1 protease Mch5 is a CrmA-inhibitable protease that activates multiple Ced-3/ICE-like cysteine proteases. Proc. Natl. Acad. Sci. U.S.A. 93: 14486-14491.
45. Tamura T, Ueda S, Yoshida M, Matsuzaki M, Mohri H, Okubo T. (1996) IFN-gamma induces ICE gene expression and enhances cellular susceptibility to apoptosis in the U937 leukemia cell line. Biochem. Biophys. Res. Commun. 229: 21-26.
46. Su X, Zhou T, Wang Z, Yang P, Jope RS, Mountz JD. (1995) Defective expression of hematopoietic cell protein tyrosine phosphatase (HCP) in lymphoid cells blocks Fas-mediated apoptosis. Immunity 2: 353-362.
47. Itoh N, Tsujimoto Y, Nagata S. (1993) Effect of bcl-2 on Fas antigen-mediated cell death. J. Immunol. 151: 621-627.
48. Weller M, Malipiero U, Aguzzi A, Reed JC, Fontana A. (1995) Protooncogene bcl-2 gene transfer abrogates Fas/APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation. J. Clin. Invest. 95: 2633-2643.
49. Jaattela M, Benedict M, Tewari M, Shayman JA, Dixit VM. (1995) Bcl-x and bcl-2 inhibit TNF and Fas-induced apoptosis and activation of phospholipase A2 in breast carcinoma cells. Oncogene 10: 2297-2305.
50. Bargou RC, Daniel PT, Mapara MY, et al. (1995) Expression of the bcl-2 gene family in normal and malignant breast tissue: Low bax-alpha expression in tumor cells correlates with resistance towards apoptosis. Int. J. Cancer 60: 854-859.
51. Bargou RC, Wagener C, Bommert K, et al. (1996) Overexpression of the death-promoting gene bax-alpha which is downregulated in breast cancer restores sensitivity to different apoptotic stimuli and reduces tumor growth in SCID mice. J. Clin. Invest. 97: 2651-2659.
52. Tamura T, Aoyama N, Saya H, et al. (1995) Induction of Fas-mediated apoptosis in p53-transfected human colon carcinoma cells. Oncogene 11: 1939-1946.
53. Owen-Schaub LB, Zhang W, Cusack JC, et al. (1995) Wild-type human p53 and a temperature-sensitive mutant induce Fas/ APO-1 expression. Mol. Cell Bid. 15: 3032-3040.
54. McGahon AJ, Nishioka WK, Martin SJ, Mahboubi A, Cotter TG, Green DR. (1995) Regulation of the Fas apoptotic cell death pathway by Abl. J. Biol. Chem. 270: 22625-22631.
55. Korbutt GS, Elliott JF, Rajotte RV. (1997) Cotransplantation of allogeneic islets with allogeneic testicular cell aggregates allows long-term graft survival without systemic immunosuppression. Diabetes 46: 317-322.
56. Lau HT, Yu M, Fontana A, Stoeckert CJ, Jr. (1996) Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice. Science 270: 109-112.
57. Stuart PM, Griffith TS, Usui N, Pepose J, Yu X, Ferguson TA. (1997) CD95 ligand (FasL)-induced apoptosis is necessary for corneal allograft survival. J. Clin. Invest. 99: 396-402.
58. Tanaka M, Suda T, Haze K, et al. (1996) Fas ligand in human serum. Nat. Med. 2: 317-322.
59. Zornig M, Grzeschiczek A, Kowalski MB, Hartmann KU, Moroy T. (1995) Loss of Fas/ Apo-1 receptor accelerates lymphomagenesis in E mu L-Myc transgenic mice but not in animals infected with MoMuLV. Oncogene 10: 2397-2401.
60. Peng SL, Robert ME, Hayday AC, Craft J. (1996) A tumor-suppressor function for Fas (CD95) revealed in T cell-deficient mice. J. Exp. Med. 184: 1149-1154.
61. van den Broek ME, Kagi D, Ossendorp F, et al. (1996) Decreased tumor surveillance in perforin-deficient mice. J. Exp. Med. 184: 1781-1790.
62. Irmler M, Hertig S, MacDonald HR, et al. (1995) Granzyme A is an interleukin 1 beta-converting enzyme. J. Exp. Med. 181: 1917-1922.
63. Quan LT, Caputo A, Bleackley RC, Pickup DJ, Salvesen GS. (1995) Granzyme B is inhibited by the cowpox virus serpin cytokine response modifier A. J. Biol. Chem. 270: 10377-10379.
64. Kondo S, Barna BP, Morimura T, et al. (1995) Interleukin-1β converting enzyme mediates cisplatin-induced apoptosis in malignant glioma cells. Cancer Res. 55: 6166-6171.
65. Schroter M, Lowin B, Borner C, Tschopp J. (1995) Regulation of Fas(Apo-1/CD95)- and perforin-mediated lytic pathways of primary cytotoxic T lymphocytes by the protooncogene bcl-2. Eur. J. Immunol. 25: 3509-3513.
66. Minn AJ, Rudin CM, Boise LH, Thompson CB. (1995) Expression of bcl-xL can confer a multi-drug resistance phenotype. Blood 86: 1903-1910.
67. Schott AF, Apel IJ, Nunez G, Clarke MF. (1995) Bcl-xL protects cancer cells from p53-mediated apoptosis. Oncogene 11: 1389-1394.
68. Friesen C, Herr I, Krammer PH, Debatin K-M. (1996) Involvement of the CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat. Med. 2: 574-577.
69. Müller M, Strand S, Hug H, et al. (1997) Drug-induced apoptosis in hepaloma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J. Clin. Invest. 99: 403-413.
70. Rayner AA, Grimm EA, Lotze MT. (1985) Lymphokine-activated killer (LAK) cells: Analysis of factors relevant to the immunotherapy of human cancer. Cancer 55: 1327-1333.
71. Weller M, Malipiero U, Rensing-Ehl A, Barr PJ, Fontana A. (1995) Fas/APO-1 gene transfer for human malignant glioma. Cancer Res. 55: 2936-2944.
72. Browning JL, Miatkowski K, Sizing I, et al. (1996) Signaling through the lymphotoxin-beta receptor induces the death of some adenocarcinoma tumor lines. J. Exp. Med. 183: 867-878.
73. Abreu-Martin MT, Vidrich A, Lynch DH, Targan SR. (1995) Divergent induction of apoptosis and IL-8 secretion in HT-29 cells in response to TNF-alpha and ligation of Fas antigen. J. Imnumol. 155: 4147-4154.
74. Ogasawara J, Watanabe-Fukunaga R, Adachi M, et al. (1993) Lethal effect of the anti-Fas antibody in mice. Nature 364: 806-809.
75. Rodriguez I, Matsuura K, Ody C, Nagata S, Vassalli P. (1996) Systemic injection of a tripeptide inhibits the intracellular activation of CPP32-like proteases in vivo and fully protects mice against Fas-mediated fulminant liver destruction and death. J. Exp. Med. 184: 2067-2072.